NASDAQ:CCCC

C4 Therapeutics Competitors

$32.55
-0.37 (-1.12 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$31.77
Now: $32.55
$33.29
50-Day Range
$30.71
MA: $39.07
$44.64
52-Week Range
$22.40
Now: $32.55
$48.97
Volume173,438 shs
Average Volume277,649 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

C4 Therapeutics (NASDAQ:CCCC) Vs. CBPO, ALLO, BEAM, IOVA, SWTX, and NSTG

Should you be buying CCCC stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to C4 Therapeutics, including China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), and NanoString Technologies (NSTG).

China Biologic Products (NASDAQ:CBPO) and C4 Therapeutics (NASDAQ:CCCC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Institutional and Insider Ownership

34.8% of China Biologic Products shares are held by institutional investors. 2.7% of China Biologic Products shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares China Biologic Products and C4 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Biologic Products27.43%8.32%7.64%
C4 TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares China Biologic Products and C4 Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Biologic Products$503.70 million9.24$138.81 million$4.2827.63
C4 TherapeuticsN/AN/AN/AN/AN/A

China Biologic Products has higher revenue and earnings than C4 Therapeutics.

Analyst Ratings

This is a summary of recent ratings for China Biologic Products and C4 Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Biologic Products0000N/A
C4 Therapeutics00303.00

C4 Therapeutics has a consensus price target of $44.50, indicating a potential upside of 36.71%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than China Biologic Products.

Summary

China Biologic Products beats C4 Therapeutics on 6 of the 8 factors compared between the two stocks.

Allogene Therapeutics (NASDAQ:ALLO) and C4 Therapeutics (NASDAQ:CCCC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Allogene Therapeutics and C4 Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allogene Therapeutics031302.81
C4 Therapeutics00303.00

Allogene Therapeutics currently has a consensus price target of $52.0833, suggesting a potential upside of 60.55%. C4 Therapeutics has a consensus price target of $44.50, suggesting a potential upside of 36.71%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than C4 Therapeutics.

Earnings and Valuation

This table compares Allogene Therapeutics and C4 Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-17.73
C4 TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Allogene Therapeutics and C4 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allogene TherapeuticsN/A-27.59%-24.97%
C4 TherapeuticsN/AN/AN/A

Institutional & Insider Ownership

59.9% of Allogene Therapeutics shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats C4 Therapeutics on 4 of the 7 factors compared between the two stocks.

C4 Therapeutics (NASDAQ:CCCC) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings and target prices for C4 Therapeutics and Beam Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
C4 Therapeutics00303.00
Beam Therapeutics03302.50

C4 Therapeutics presently has a consensus target price of $44.50, suggesting a potential upside of 36.71%. Beam Therapeutics has a consensus target price of $96.00, suggesting a potential upside of 31.18%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe C4 Therapeutics is more favorable than Beam Therapeutics.

Earnings & Valuation

This table compares C4 Therapeutics and Beam Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4 TherapeuticsN/AN/AN/AN/AN/A
Beam Therapeutics$20,000.00227,047.22$-78,330,000.00($14.05)-5.17

C4 Therapeutics has higher earnings, but lower revenue than Beam Therapeutics.

Profitability

This table compares C4 Therapeutics and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
C4 TherapeuticsN/AN/AN/A
Beam Therapeutics-529,075.00%-103.41%-48.05%

Institutional and Insider Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

C4 Therapeutics beats Beam Therapeutics on 5 of the 8 factors compared between the two stocks.

C4 Therapeutics (NASDAQ:CCCC) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Earnings & Valuation

This table compares C4 Therapeutics and Iovance Biotherapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4 TherapeuticsN/AN/AN/AN/AN/A
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-18.96

Institutional and Insider Ownership

94.6% of Iovance Biotherapeutics shares are held by institutional investors. 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares C4 Therapeutics and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
C4 TherapeuticsN/AN/AN/A
Iovance BiotherapeuticsN/A-50.64%-45.64%

Analyst Recommendations

This is a breakdown of current ratings and target prices for C4 Therapeutics and Iovance Biotherapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
C4 Therapeutics00303.00
Iovance Biotherapeutics011002.91

C4 Therapeutics presently has a consensus target price of $44.50, suggesting a potential upside of 36.71%. Iovance Biotherapeutics has a consensus target price of $50.50, suggesting a potential upside of 64.87%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than C4 Therapeutics.

Summary

Iovance Biotherapeutics beats C4 Therapeutics on 4 of the 7 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and C4 Therapeutics (NASDAQ:CCCC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of recent ratings for SpringWorks Therapeutics and C4 Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00403.00
C4 Therapeutics00303.00

SpringWorks Therapeutics currently has a consensus price target of $95.20, suggesting a potential upside of 33.26%. C4 Therapeutics has a consensus price target of $44.50, suggesting a potential upside of 36.71%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than SpringWorks Therapeutics.

Earnings and Valuation

This table compares SpringWorks Therapeutics and C4 Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.72
C4 TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares SpringWorks Therapeutics and C4 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
C4 TherapeuticsN/AN/AN/A

Institutional and Insider Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

C4 Therapeutics (NASDAQ:CCCC) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for C4 Therapeutics and NanoString Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
C4 Therapeutics00303.00
NanoString Technologies01402.80

C4 Therapeutics currently has a consensus price target of $44.50, suggesting a potential upside of 36.71%. NanoString Technologies has a consensus price target of $68.60, suggesting a potential downside of 6.04%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe C4 Therapeutics is more favorable than NanoString Technologies.

Earnings and Valuation

This table compares C4 Therapeutics and NanoString Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4 TherapeuticsN/AN/AN/AN/AN/A
NanoString Technologies$125.57 million25.92$-40,700,000.00($1.93)-37.83

C4 Therapeutics has higher earnings, but lower revenue than NanoString Technologies.

Profitability

This table compares C4 Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
C4 TherapeuticsN/AN/AN/A
NanoString Technologies-53.47%-68.96%-24.15%

Insider & Institutional Ownership

98.3% of NanoString Technologies shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

C4 Therapeutics beats NanoString Technologies on 5 of the 9 factors compared between the two stocks.


C4 Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.26-0.2%$4.65 billion$503.70 million33.03
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.44-1.3%$4.62 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.69-1.5%$4.54 billion$20,000.00-5.17
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.14-1.0%$4.43 billionN/A-15.70Analyst Report
Increase in Short Interest
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$70.01-5.1%$3.43 billionN/A-40.24Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$73.01-1.6%$3.25 billion$125.57 million-42.70Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.32-3.1%$2.96 billion$50.04 million0.00
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.60-3.5%$2.95 billionN/A0.00News Coverage
Vericel logo
VCEL
Vericel
1.1$58.62-1.1%$2.70 billion$117.85 million-5,862,000.00Increase in Short Interest
Editas Medicine logo
EDIT
Editas Medicine
1.6$34.67-18.2%$2.34 billion$20.53 million-19.93Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.49-0.7%$2.10 billion$31.43 million-5.13Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$24.30-1.0%$1.97 billionN/A-11.36Decrease in Short Interest
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.28-5.1%$1.90 billion$44.67 million-2.58
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.66-0.3%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.33-0.9%$1.72 billionN/A-52.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Immunovant logo
IMVT
Immunovant
1.8$15.42-3.0%$1.51 billionN/A-11.95Increase in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.51-3.9%$1.47 billion$35.23 million-13.92Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
AlloVir logo
ALVR
AlloVir
1.4$22.08-2.4%$1.44 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84-4.5%$1.42 billion$7.80 million-17.61
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.65-10.4%$1.21 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.77-0.4%$1.05 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39-1.0%$1.05 billion$356.07 million7.05
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.22-7.0%$935.20 millionN/A0.00Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.86-2.5%$934.53 millionN/A-4.27Insider Selling
Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01-6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86-4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86-6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$15.88-8.3%$854.84 millionN/A0.00Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.40-0.5%$829.93 million$22.99 million-10.32
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25-3.9%$809.32 million$69.89 million-4.12
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93-2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02-5.3%$744.64 million$2.51 million-3.65
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Inhibrx logo
INBX
Inhibrx
1.6$18.03-16.4%$680.60 millionN/A0.00Decrease in Short Interest
Gap Up
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.00-1.3%$648.22 million$5.78 million-9.39Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.35-1.5%$630.05 million$9.86 million-9.07
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.08-1.6%$623.24 million$13.29 million-9.99
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.59-0.8%$615.82 millionN/A0.00Analyst Downgrade
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.